• Gross Revenue: BRL10.7 billion, a 15% increase year-on-year.

• Adjusted EBITDA: BRL810 million, a 23.2% growth with a margin of 7.5%.

• EBT (Earnings Before Tax): Increased by 44.7% year-on-year.

• Free Cash Flow: BRL700 million.

• Store Openings: 72 new stores opened, totaling 3,139 units.

• Digital Sales: BRL1.2 billion, a 40.2% increase.

• Same-Store Sales Growth: 9.1% year-on-year.

• Gross Profit Margin: 27.6%, totaling BRL2.97 billion.

• Net Income Margin: 3.1%, up from 2.9% the previous year.

• Cash Cycle: 59.6 days.

• Market Share Increase: 0.3 percentage points overall, with regional increases in Sao Paulo (0.6%) and the Northeast (0.7%).

• Net Promoter Score (NPS): Maintained at 91%.

• Warning! GuruFocus has detected 1 Warning Sign with RADLY.

Release Date: November 06, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Raia Drogasil SA (RADLY) reported a record-breaking quarter with the opening of 72 new stores, bringing the total to 3,139 units.

• The company achieved a strong Net Promoter Score (NPS) of 91%, indicating high customer satisfaction.

• Gross revenue increased by 15% to BRL10.7 billion, with a notable 40.2% growth in digital sales.

• Adjusted EBITDA grew by 23.2% to BRL810 million, with a margin of 7.5%, driven by a reduction in G&A expenses.

• Raia Drogasil SA (RADLY) is expanding its presence in smaller towns, enhancing its market reach and competitive edge.

Negative Points

• The company faces challenges with regulatory price increases and potential changes in taxation, which could impact future margins.

• There is a noted deceleration in market share gains, with increased competition in certain regions.

• The health services segment is still not profitable, with a reported loss, and regulatory changes are needed for it to take off.

• Personnel costs may rise due to a heated labor market, potentially impacting selling expenses.

• The company experienced a temporary undersupply of Ozempic due to strategic shifts by suppliers, affecting operations.

Q & A Highlights

Q: Can you provide more details about the expected margin improvements and any potential risks from regulatory price increases or taxation changes? A: Marcilio Pousada, CEO: The dilution of G&A expenses is expected to continue, contributing to margin improvements. We are committed to maintaining high productivity in our stores and will invest in personnel if necessary to enhance customer service. Regulatory price increases are a regular occurrence, and we have strategies to mitigate their impact. Our working capital management remains efficient, with a focus on optimizing inventory levels.